Therapy Areas: Diabetes
AgeX Therapeutics Receives Extension of Time to Attain Compliance with Stock Exchange Continued Listing Requirements
25 November 2022 - - US-based biotechnology company AgeX Therapeutics, Inc. (NYSE American: AGE) received notification from the staff of the NYSE American that the Exchange has accepted a revised listing compliance plan from AgeX and has granted AgeX an extension of time to regain compliance with the Exchange's continued listing standards as set forth in Section 1003(a) (i) and of the Exchange company Guide by increasing its stockholders equity to not less than USD 4m, the company said.

The Exchange staff will periodically review AgeX's adherence to the plan milestones. If AgeX is not in compliance with the continued listing standards by May 17, 2023, or if AgeX does not make progress consistent with the plan during the plan period, the Exchange will initiate delisting proceedings as appropriate.

AgeX said it plans to make arrangements to have its common stock quoted on an electronic interdealer quotation system if its common stock is delisted from the Exchange.

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics to treat human diseases to increase healthspan and combat the effects of aging.

AgeX's PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need.

AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.

AgeX's revolutionary longevity platform induced Tissue Regeneration aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues.

HyStem is AgeX's delivery technology to stably engraft PureStem or other cell therapies in the body.

AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.
Login
Username:

Password: